Bioregulators & Organ Support
Cartalax
← Back to Library
Limited / unverified Limited / unverified Limited / unverified Repair Bioregulator
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 20 mg
Dosing window: Anytime
Receptor / target: Cartilage
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 1mg 1x Daily | Take at bedtime fasted. Repeat 3-4 times per year. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative Titration 1: Extended Protocol (Goal: deep cartilage matrix restoration for subjects with moderate-to-severe osteoarthritis; higher cumulative dose through extended lower-intensity daily exposure)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 5mg 1x Daily at bedtime fasted | Higher-dose extended cycle. For significant osteoarthritis burden where maximal chondrocyte gene program normalization is the objective. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 2: BPC-157 + TB-500 + Cartalax Joint Repair Triple Stack (Goal: comprehensive articular joint tissue restoration targeting chondrocyte gene programs (Cartalax), periarticular vasculature and tendon repair (BPC-157), and cytoskeletal repair mechanics (TB-500) simultaneously)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 1mg Cartalax at bedtime fasted | Most complete joint repair protocol in the database. Cartalax at bedtime. 250mcg BPC-157 and 2mg TB-500 at their standard schedules (can be co-administered in morning injection). Assess joint pain VAS and ROM at day 0, day 20, and day 60. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 3: Athletes Joint Preservation Protocol (Goal: proactive articular cartilage maintenance for competitive athletes with high joint loading; quarterly cycling to stay ahead of cumulative mechanical cartilage stress)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 (quarterly) | 1mg 1x Daily at bedtime fasted | Proactive rather than reactive protocol. Begin before symptoms develop. Align with off-season training blocks where joint loading is lowest: this is when synovial fluid bioregulator diffusion is most effective without competing mechanical compression from heavy training. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 4: Post-Orthopedic Surgery Cartilage Rehabilitation Protocol (Goal: accelerate articular cartilage healing post-arthroscopy, microfracture surgery, or ACI procedure; minimum 6 weeks post-op, surgeon clearance required)
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-2 | 500mcg 1x Daily at bedtime fasted | Minimum 6 weeks post-surgical. Surgeon clearance required. Conservative entry during early weight-bearing rehabilitation. |
| Weeks 3-4 | 1mg 1x Daily at bedtime fasted | |
| Weeks 5-12 | 1mg 1x Daily at bedtime fasted | Extended recovery cycle. Add BPC-157 from week 3 for periarticular vascular and tendon support. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Alternative Titration 5: Teriparatide + Cartalax Bone and Cartilage Joint Stack (Goal: simultaneous subchondral bone restoration (Teriparatide) and articular cartilage gene program normalization (Cartalax) for subjects with combined osteoarthritis and osteoporosis)
| Timeframe | Dose | Notes |
|---|---|---|
| Days 1-20 | 1mg Cartalax at bedtime fasted | 20mcg Teriparatide 1x Daily in the morning; Cartalax is dosed at bedtime fasted. This addresses both articular cartilage (Cartalax) and subchondral bone quality (Teriparatide) simultaneously. Mechanistically complementary: subchondral bone quality directly affects articular cartilage biomechanics. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Bioregulator protocols are often cycle-based because the claim is organ-system signaling rather than acute symptom control. The logic should be organ-specific labs, medical context, and humility about older or vendor-derived evidence. Entry context: target (Cartilage); route Subcutaneous; timing Anytime. Limited-evidence dosing tables are hypotheses, not recommendations.
Independent evidence
Independent safety notes: No independent approved-label regimen is listed for this entry. Dosing notes remain unverified.
Regulatory status: no approved label identified
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Active septic arthritis: bioregulator chondrocyte activity during active bacterial joint infection is contraindicated; antimicrobial treatment and joint drainage are the priority. Limited / unverified
- Active inflammatory arthritis in acute flare (rheumatoid arthritis, psoriatic arthritis, gout flare): the inflammatory milieu of acute arthritic flare creates a poor context for chondrocyte gene program normalization; Cartalax is a chronic bioregulator for non-inflammatory cartilage restoration. Limited / unverified
- Chondrosarcoma or malignant bone/cartilage tumors: chondrocyte bioregulator activity in the context of malignant cartilage cells has not been evaluated. Limited / unverified
- Known hypersensitivity to Cartalax (Ala-Glu-Asp tripeptide) or formulation excipients. Limited / unverified
- Pregnancy: cartilage and connective tissue bioregulator effects during pregnancy have not been evaluated. Limited / unverified
- Recent total joint arthroplasty: in subjects who have undergone total hip or knee replacement, the articular cartilage that Cartalax targets has been surgically removed; the bioregulator has no relevant target tissue in fully replaced joints. Limited / unverified
- Concurrent high-dose systemic corticosteroids: corticosteroids suppress chondrocyte anabolic activity and inhibit proteoglycan synthesis through mechanisms that could counteract Cartalax's anabolic chondrocyte gene program normalization. Limited / unverified
- Active biologic DMARD therapy for RA (tocilizumab, abatacept): the immunological context of active biologic DMARD use for RA represents an unpredictable environment for chondrocyte bioregulator activity; the cartilage is a target of ongoing autoimmune destruction that must be addressed at the inflammatory level first. Limited / unverified
Side effects (limited evidence)
- Mild transient joint discomfort: as chondrocyte metabolic activity increases and cartilage matrix remodeling begins, some subjects report mild transient joint ache in the first 3-5 days of a new cycle; reflects active cartilage bioregulator activity rather than damage; typically self-limiting. Limited / unverified
- Mild increased joint warmth: uncommon; related to synovial fluid metabolic activity changes as chondrocyte and synoviocyte gene programs normalize; typically resolves within the first week. Limited / unverified
- Injection site mild reaction: standard subcutaneous peptide response. Limited / unverified
- Mild morning stiffness changes: as cartilage water content and proteoglycan composition normalize over the cycle, some subjects notice transient changes in morning joint stiffness duration; typically trending toward improvement over the cycle. Limited / unverified
- No serious musculoskeletal adverse events documented in the Khavinson research literature: Cartalax's safety profile in osteoarthritis and aging joint tissue populations is clean at standard protocol doses. Limited / unverified
- Unknown interaction with intra-articular corticosteroid or hyaluronic acid injections: subjects receiving concurrent intra-articular injections should coordinate timing with Cartalax cycles; no documented interactions exist but the local joint environment during active intra-articular injection therapy has not been specifically studied with concurrent Cartalax use. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.